**Core Concept**
The treatment of Parkinson's disease involves various pharmacological strategies to manage symptoms such as tremors, rigidity, and bradykinesia. Transdermal drug delivery systems, including transcranial patches, are being explored as an alternative to traditional oral medications to improve patient compliance and reduce side effects.

**Why the Correct Answer is Right**
Rotigotine is a non-ergoline dopamine agonist that is used in the treatment of Parkinson's disease. It acts by directly stimulating dopamine receptors in the brain, thereby alleviating symptoms of the disease. Rotigotine is available in a transdermal patch formulation, which allows for continuous drug delivery and helps maintain stable plasma concentrations. This formulation also reduces the risk of gastrointestinal side effects associated with oral medications.

**Why Each Wrong Option is Incorrect**
**Option A:** (No information provided)
**Option B:** (No information provided)
**Option C:** (No information provided)
**Option D:** (No information provided)

**Clinical Pearl / High-Yield Fact**
Rotigotine is a good example of a transdermal patch used in the treatment of Parkinson's disease. It's essential to remember that transdermal drug delivery systems can provide continuous drug release, improving patient compliance and reducing side effects associated with oral medications.

**Correct Answer:** C. Rotigotine